BALA CYNWYD, Pa., June 23, 2009 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Monogram Biosciences, Inc. ("Monogram Biosciences" or the "Company") (Nasdaq:MGRM) relating to the proposed acquisition by Laboratory Corporation of America Holdings ("LabCorp") (NYSE:LH). LabCorp has agreed to acquire Monogram Biosciences in an all-cash deal valued at approximately $106.7 million ($155 million, including indebtedness).
Under the proposed agreement, Monogram Biosciences shareholders will receive $4.55 for every share of Monogram Biosciences common stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law related to the Monogram Biosciences Board's approval of the proposed merger. The transaction appears to be unfair, in part, given that Monogram Biosciences stock was trading at over $4.35 a share as recently as February 2009 and traded at over $5.00 a share into the 4th quarter of 2008.
If you own shares of Monogram Biosciences and wish to discuss the legal ramifications of the proposed acquisition by LabCorp, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Marc Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at clients@brodsky-smith.com, or by calling toll free 877-LEGAL-90.